Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869779 | 1.00 | ANPEP (0.45) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5870379 | 0.88 | ANPEP (0.45) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5870383 | 0.88 | ANPEP (0.45) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5870377 | 0.88 | ANPEP (0.45) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5869849 | 0.87 | CTSK (0.46) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5869851 | 0.87 | CTSK (0.46) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5869855 | 0.87 | CTSK (0.46) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5869690 | 0.85 | ANPEP (0.50) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5869462 | 0.85 | ANPEP (0.50) | ANPEPCTSKCTSLCTSSCAPN1 | |
| SCHEMBL5869470 | 0.85 | ANPEP (0.50) | ANPEPCTSKCTSLCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ANPEP 118/4885CTSK 541/4885CTSL 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.